The 21-gene Recurrence Score® (RS) assay (Oncotype DX®, Genomic Health Inc., Redwood City, CA) is used to guide treatment decisions in estrogen receptor (ER) + early-stage breast cancer (BC) for more than a decade. The gene discussed is ESR1; the disease is breast carcinoma.